Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06MRY
|
|||
| Former ID |
DIB006868
|
|||
| Drug Name |
Enteric-coated mycophenolate sodium
|
|||
| Synonyms |
Myfortic; Mycophenolate sodium; ERL-080; Enteric-coated MPA, Novartis; Enteric-coated mycophenolate sodium, Novartis
Click to Show/Hide
|
|||
| Indication | Transplant rejection [ICD-11: NE84; ICD-9: 279.5, 996] | Approved | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Purine metabolism | |||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | Purine ribonucleoside monophosphate biosynthesis | |||
| WikiPathways | Nucleotide Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.